<SEC-DOCUMENT>0001387131-18-001328.txt : 20180402
<SEC-HEADER>0001387131-18-001328.hdr.sgml : 20180402
<ACCEPTANCE-DATETIME>20180402070112
ACCESSION NUMBER:		0001387131-18-001328
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180327
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180402
DATE AS OF CHANGE:		20180402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		18727211

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_032718.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>

<HEAD>
    <TITLE>txmd-8k_032718.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <div align="LEFT" style="margin: 0;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0;">&nbsp;</p>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>UNITED STATES</b></font>
    </p>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></font>
    </p>
    <p style="margin: 0; padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Washington, D.C. 20549</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;</font>
    </p>
    <p style="margin: 0 0 14.3pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">FORM 8-K</font>
    </p>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>CURRENT REPORT</b></font>
    </p>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>PURSUANT TO SECTION 13 OR 15(d) OF THE</b></font>
    </p>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">SECURITIES EXCHANGE ACT OF 1934</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Date of Report (Date of earliest event reported): March 27, 2018&nbsp;</font>
    </p>
    <p style="margin: 1.1pt 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; padding: 0; width: 100%; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>TherapeuticsMD, Inc.</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-left: 5.5pt; padding-right: 5.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Exact Name of Registrant as Specified in its Charter)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; text-align: center; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Nevada</b></font>
            </td>
            <td style="width: 2%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>001-00100</b></font>
            </td>
            <td style="width: 2%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 32%; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>87-0233535</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(State or Other</font>
                </p>
                <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Jurisdiction of Incorporation)</font>
                </p>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Commission File Number)</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(IRS Employer</font>
                </p>
                <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Identification No.)</font>
                </p>
            </td>
        </tr>
    </table>
    <p style="margin: 0; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="border-bottom: black 1pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif;">
                <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">6800 Broken Sound Parkway NW, Third Floor</font>
                </p>
                <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
                    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Boca Raton, FL 33487</font>
                </p>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Address of Principal Executive Office) (Zip Code)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; text-align: center; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Registrant's telephone number, including area code: (561) 961-1900</font>
    </p>
    <p style="margin: 0; text-align: center; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0 0 14.3pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2 below):</font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2610;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2610;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2610;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; padding: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#x2610;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font>
    </p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#xA7; 230-405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#xA7;240.12b-2 of this chapter).</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Emerging growth company &#x2610;</font>
    </p>
    <p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence:  1; -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%">&nbsp;</td>
                <td style="width: 33%">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <table cellpadding="0" cellspacing="0" style="width: 100%">
            <tr>
                <td style="text-align: center; width: 100%">&nbsp;</td>
            </tr>
        </table>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 13.2pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <p style="margin-bottom: 0; margin-top: 0;">
                    <font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 5.02.</b></font>
                </p>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0 0 13.2pt; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On March 27, 2018, the Board of Directors (the &#x201C;<u>Board</u>&#x201D;) of TherapeuticsMD, Inc., a Nevada corporation (the &#x201C;<u>Company</u>&#x201D;), appointed Ms. Jane F. Barlow, M.D., M.B.A, M.P.H. to serve as a director of the Company.</font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Board has determined that Dr. Barlow is independent under the rules of the NASDAQ Global Select Market.</font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0 0 13.2pt; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As director of the Company, Dr. Barlow will receive compensation in the same manner as the Company&#x2019;s other non-employee directors.&nbsp;&nbsp;</font>
    </p>
    <p style="margin: 0 0 13.2pt; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Dr. Barlow has not been appointed to any committees of the Board at this time.</font>
    </p>
    <p style="margin: 0 0 13.2pt; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">There are no arrangements or understandings between Dr. Barlow and any other person pursuant to which Dr. Barlow was appointed as a director of the Company. Other than as described in this Current Report on Form 8-K, since the beginning of the Company&#x2019;s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which Dr. Barlow was or is to be a participant and in which any related person had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.</font>
    </p>
    <table style="margin-bottom: 11pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 7.01.</b></font>
            </td>
            <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Regulation FD Disclosure.</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0 0 11pt; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On April 2, 2018, the Company issued a press release announcing the appointment of Ms. Jane F. Barlow, M.D., M.B.A, M.P.H. to the Board. A copy of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be &#x201C;filed&#x201D; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</font>
    </p>
    <table style="margin-bottom: 11pt; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 9.01.</b></font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Financial Statements and Exhibits.</b></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; padding: 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp; <i>Exhibits.</i></font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;&nbsp;</font>
    </p>
    <p style="margin: 0px; line-height: normal; text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"><strong><font style="text-decoration: underline;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Exhibit Index</font></font></strong></p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 1in; font: 10pt Times New Roman, Times, Serif;" nowrap>
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Exhibit Number</u></font>
            </td>
            <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Description</u></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="padding-top: 5.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">99.1</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="padding-top: 5.5pt; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><a href="ex99-1.htm">Press release dated April 2, 2018.</a></font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&nbsp;</b></font>
    </p>
    <!-- Field: Page; Sequence:  2; -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%">&nbsp;</td>
                <td style="width: 33%">&nbsp;</td>
            </tr>
        </table>
    </div>
    <div style="page-break-before: always; margin-top: 6pt">
        <table cellpadding="0" cellspacing="0" style="width: 100%">
            <tr>
                <td style="text-align: center; width: 100%">&nbsp;</td>
            </tr>
        </table>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0 0 12.1pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>SIGNATURES</b></font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 29.7pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
    </p>
    <p style="margin: 0; text-align: justify; text-indent: 29.7pt; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Date:&nbsp;&nbsp;April 2, 2018</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">THERAPEUTICSMD, INC.</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;" colspan="2">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="width: 50%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="width: 8%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">By:</font>
            </td>
            <td style="border-bottom: black 1pt solid; width: 42%; font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/ <i>Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Name:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Title:</font>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Financial Officer</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence:  3; Options:  Last; -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt">
            <tr style="vertical-align: top; text-align: left">
                <td style="width: 33%">&nbsp;</td>
                <td style="width: 34%">&nbsp;</td>
                <td style="width: 33%">&nbsp;</td>
            </tr>
        </table>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE DATED APRIL 2, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_032718.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0 274.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_img001.jpg" ALT="" STYLE="height: 31px; width: 269px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0 314pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05in 88.9pt 0 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
IMMEDIATE RELEASE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TherapeuticsMD
Announces Expansion of Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4.3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>-
Dr. Jane F. Barlow Appointed as Independent Director - </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOCA
RATON, Florida, April 2, 2018</B> &#8211; TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women&#8217;s healthcare company,
today announced the appointment of Jane F. Barlow, M.D., M.B.A., M.P.H. as an independent director to the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Barlow previously served as Associate Chief Medical Officer for CVS Health and Chief Medical Officer of CVS Health&#8217;s Medicare
and Government Services business segment, where she drove clinical strategies supporting drug purchasing, distribution, and utilization
management for over five billion annual prescriptions. Prior to CVS Health, she served as Vice President of Clinical Innovation
at MEDCO Health Solutions, focused on clinical innovations into all aspects of pharmacy and pharmacy benefits management for over
60 million members. Dr. Barlow is currently the Chief Executive Officer of Jane Barlow &amp; Associates, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Barlow is a clinical and strategic executive with over 25 years of leadership experience in driving cost-effective medical, diagnostic,
and pharmaceutical strategies, directing corporate health benefits, delivering patient care, and supporting health systems. She
is a recognized leader in payer reimbursement, health policy, technology, quality and compliance, benefits design, and population
health management. Dr. Barlow is active in evaluating the economic impact and value of pharmaceuticals and diagnostics to aid
payers and manufacturers in defining access and coverage strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;We
are very pleased to add Dr. Barlow as the newest independent director to our Board. She has a wealth of experience as both a director
and a member of senior management at successful healthcare organizations,&#8221; said TherapeuticsMD CEO Robert G. Finizio. &#8220;This
is an exciting time in our company&#8217;s growth and development, and Dr. Barlow&#8217;s skill set complements our transformation
to a commercial organization in the years ahead.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.15pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
TherapeuticsMD, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA&#8482;
technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes. The Company&#8217;s late stage clinical pipeline includes
two product candidates that have completed phase 3 trials and are awaiting approval by the FDA: TX-001HR for treatment of moderate-to-severe
vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse
(dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The Company also manufactures and distributes branded
and generic prescription prenatal vitamins under the vitaMedMD&reg; and BocaGreenMD&reg; brands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD&#8217;s objectives, plans and strategies as well as statements,
other than historical facts, that address activities, events or developments that the company intends, expects, projects,
believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as
&#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221; &#8220;should,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221;
&#8220;projects,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions and are based on assumptions
and assessments made in light of management&#8217;s experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release
are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties, many of which are outside of the company&#8217;s control.
Important factors that could cause actual results, developments and business decisions to differ materially from
forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in the company&#8217;s filings
with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as reports on Form 8-K, and include the following: the company&#8217;s ability to resolve the deficiencies
identified by the FDA in the company&#8217;s new drug application for its TX-004HR product candidate and the time frame
associated with such resolution; whether the FDA will approve the amended NDA for the company&#8217;s TX-004HR product
candidate and whether such approval will occur by the PDUFA target action date; whether the FDA will approve the NDA for the
company&#8217;s TX-001HR product candidate and whether such approval will occur by the PDUFA target action date; the
company&#8217;s ability to maintain or increase sales of its products; the company&#8217;s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and
uncertain results of the company&#8217;s clinical trials, including any additional clinical trials that the FDA may require
in connection with TX-004HR; the potential of adverse side effects or other safety risks that could preclude the approval of
the company&#8217;s hormone therapy drug candidates; the company&#8217;s reliance on third parties to conduct its
clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities
and health insurance companies for the company&#8217;s products; the impact of product liability lawsuits; the influence of
extensive and costly government regulation; the volatility of the trading price of the company&#8217;s common stock and the
concentration of power in its stock ownership. PDF copies of the company&#8217;s historical press releases and financial
tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
# #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.35pt; text-indent: -5.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.35pt; text-indent: -5.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Investor
Contact</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.5pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
DeLucia</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">561-961-1900</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David.DeLucia@TherapeuticsMD.com&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 274.5pt 0 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# D4# 2(  A$! Q$!_\0
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MI&940N[!549))P *Q_\ A+_#(./^$BTC_P #8_\ XJFDWL)M+=FS14<$\-S
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MX<^%M]:+M:=A&]Q(#G>_F)G'L.@_Q)JA\(NNL?\ ;'_V>NI^('_(CZE](_\
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M<=5&<X/5L'D5CAXMU%8WQ,DJ3OU-'X!_\S#_ -NW_M6O4?$W_(J:Q_UXS?\
MH!KR[X!_\S#_ -NW_M6O5=?@DNO#FIV\*EI9;25$4=R4( JJ_P#&^XG#_P !
M?/\ 4^<OA?\ \E(T?_?D_P#1;5]/5\L_#J[AL?B#HTT[%4,_EY]W4H/U85]3
M56+^-$8+X'ZA7C/Q\_YE[_MY_P#:5>S5XS\?/^9>_P"WG_VE6>'_ (B-,5_"
M9L_ W_D2;S_L(O\ ^BXZ\0GWP^)9/[2W.Z7A^TYZDA_F_K7M_P #?^1)O/\
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M2&W2QS0H6\E.I63J1M'\1X(YZY Q[;Q=XNG"65MK>K2O(P5$CG=G8]@,'=^
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M-2S']XIX KRK2!XPT'SO[,L-0@\[;YG^A%LXSC[RGU->[45M3K<D>6US@Q.
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
